Extract
Note: Please read the
complete full text with Figures and Tables at
Introduction
Signalling transduction molecule(s)
through B cell antigen receptor (BCR) are considered to play a
crucial role in the regulation of B cell fate. The engagement of BCR
leads to activation or inactivation of B cells, depending on B cell
developmental stage as well as interaction with other cells
including T cells expressing CD40 ligand (CD40L)[1-3].
The molecular mechanisms underlying BCR-mediated activation and/or
inactivation remain largely unresolved. WEHI-231 B lymphoma cells,
representing immature stage of B cells, have been widely used as an
in vitro model system to analyze B cell-unresponsiveness[4-6],
since costimulation with CD40L rescues anti-IgM-induced growth
arrest and/or apoptosis[7,8].
The basic helix-loop-helix (bHLH)
family of transcription factors including E2A play a key role in
proliferation and/or differentiation in a variety of cell types[9,10].
The E protein contains a highly conserved HLH dimerization domain
and a DNA-binding basic region that binds a conserved E-box. Another
category of HLH protein, the inhibitor of differentiation (Id)
family possess homologous HLH domain, but not DNA-binding domain[11,12].
Thus, Id proteins function as a dominant-negative (dn) regulator of
transcription upon binding with other HLH proteins. The Id proteins
are thought to promote cell cycle progression from G1 to S phase,
while E2A proteins are thought to prevent it[9,13]. These
findings indicate that E2A/Id proteins function to promote or
inhibit proliferation in a context of cell types in divergent
stimuli. For example, mature B cells from Id3-deficient mice failed
to proliferate in response to anti-IgM[14]. Contrary to
this current notion, we have recently demonstrated that
anti-IgM-induced G1 arrest appears to result from the
anti-IgM-induced upregulation of Id3 expression at both mRNA and
protein levels in WEHI-231 cells[15], as reported in
other cell types[16]. In the present study, we examined
whether anti-IgM-induced upregulation of Id3 mRNA resulted from
transcriptional regulation of the Id3 gene.
Materials and methods
Cell culture
WEHI-231 B lymphoma cells were
maintained in RPMI-1640 medium supplemented with 10% fetal bovine
serum (FBS), 2-mercaptoethanol 50 µmol/L, and kanamycin 100 mg/L at
37 ºC in 5% CO2.
Isolation of 5'-flanking
region of mouse Id3 Genomic DNA was extracted from WEHI-231
cells using QIAGEN Genomic DNA Kit according to the manufacturer's
instruc-tion. DNA fragments corresponding to the 5'-flanking region
of the mouse Id3 gene were isolated from the genomic DNA by
polymerase chain reaction (PCR) using Id3-specific primers and high
fidelity KOD DNA polymerase (Toyobo Co, Ltd, Japan) (Figure 1),
based on the reported nucleotide sequences (GenBank accession
number, AL935264). The nucleotide sequences of the primers were the
following: forward with a Kpn I restriction enzymatic site
underlined, Id3
-1981/+54, (5'-CGGGGTACCCATACAGAAGTCTTCA-CGAGAG-3); Id3-1012/+54
(5'-CGG GGTACC TGGCTGCC-CTTCCACAACAG-3'); Id3 -200/+54 (5'-CGG
GGTACC TCCTCGCATCCGAGGCTCC-3'). Reverse for the three fragments with
a Hind III restriction enzymatic site underlined, (5'-CGG
AAGCTT GAGAGTAGAGATAGAGAGGGAG-3'). The DNA fragments Id3 -1981/+54
(Id3/2k), Id3 -1012/+54 (Id3/1k), and Id3 -200/+54 (Id3/254) were
cloned into pCR-Blunt II-TOPO vector by Zero Blunt PCR Cloning Kit (Invitrogen,
USA). The nucleotide sequences of the fragments were confirmed to be
identical to the reported sequences (GenBank) using ABI PRISM
BigDyeTM Terminator Cycle Sequencing Ready Reaction Kits (Applied
Biosystems, USA).
Plasmid construction for
transient transfection assay The fragments of the Id3 promoter
spanning nucleotides
-1981/+54, -1012/+54, and -200/+54 were subcloned into the firefly
luciferase reporter PGV-B2 vector lacking the promoter and enhancer
(Tokyo-Inki, Tokyo, Japan) (Id3/PBV-B2), as previously described[17],
resulting in Id3/2k-Luc, Id3/1k-Luc, and Id3/254-Luc, respectively.
Transient transfection of WEHI-231
cells was carried out by an electroporation method[17].
WEHI-231 cells (1.2”Į107 per 0.7 mL) containing 20 mg of
the reporter constructs and 400 ng of internal control pRL-CMV
Renilla luciferase vector were pulsed (400 V, 500 µF) using Gene
Pulser (Bio-rad, USA). Following a 24-h incubation, the cells were
further stimulated with 10 mg/L anti-IgM mAb or medium alone for 24
h, or cocultured with irradiated CD40L-expressing NIH3T3 cells or
control NIH3T3 cells. The cells were harvested and lysed in lysis
buffer (Promega, USA), followed by an assay for luciferase activity
using a Dual-Luciferase Reporter Assay System (Promega), according
to the manufacturer's instruc-tions. Both firefly and Renilla
luciferase activities were monitored with a Lumat LB9507 luminometer
(Bert-hold). The ratio of firefly/renila values was caculated to
normalize report activity. Normalized data are expressed as relative
luciferase activity compared with that seen for PGV-B2 vector alone.
Statistical analysis Data
were expressed as mean”ĄSD. For single comparison, statistical
significance between groups was determined by Student's t-test.
Significance for multiple comparisons was determined by one-way
ANOVA. P<0.05 was considered to indicate statistically
significant differences.
Results
Structure of the functional Id3
locus We have recently found
that anti-IgM upregulated Id3 mRNA expression, while CD40L
downregulated it in WEHI-231 cells[15]. To analyze
whether engagement of mIg influences transcriptional regulation of
the Id3 gene, the three fragments containing the 5'-flanking region
of the murine Id3 gene were isolated by PCR using Id3-specific
primers. These fragments were subcloned into PGV-B2 vector to
measure the promoter activity of the Id3 gene (Figure 2). Nucleotide
sequence analysis confirmed the fidelity of the all constructs
generated.
Basal promoter activity in the 5'-flanking
region of the Id3 gene WEHI-231 cells were transfected with the
constructs Id3/2k-Luc, Id3/1k-Luc, or Id3/254-Luc in combination
with internal control vector and incubated with medium alone for 24
h, followed by assay for luciferase activity (Figure 3A, 3B). The
basal promoter activity in these fragments Id3/2k, Id3/1k, or
Id3/254 was increased 24-fold, 36-fold, and 54-fold, respectively,
compared with the control vector (Figure 3B). These results suggest
that the 254-bp fragment contains some positive regulatory element(s)
of the Id3 gene, as reported by Yeh and Lim[18]. It is
also possible that there are putative negative regulatory elements
in the region from
-1981 to -201.
Anti-IgM, but not CD40L,
upregulates the promoter activity of the Id3 gene To examine
whether transcriptional regulation is involved in the anti-IgM-induced
upregulation of the Id3 gene, the WEHI-231 cells co-transfected with
the Id3/2k-Luc, Id3/1k-Luc, Id3/254-Luc constructs and internal
control vector were stimulated with 10 mg/L anti-IgM for
24 h, followed by assay for luciferase activity. The stimulation
with anti-IgM enhanced the promoter activity of the Id3 gene which
increased up to two-fold as compared with the activities in
unstimulated cells, as assessed by luciferase activity (Figure 4A).
The CD40L stimulation slightly decreased it, but the difference was
not statistically significant (Figure 4B).
In our previous study, with Northern
blot assay we observed an upregulation of Id3 mRNA expression in
WEHI-231 cells after anti-IgM stimulation to reach levels 5-fold
greater than that seen in unstimulated cells. There are many reasons
to explain the inconsistent results between luciferase activity
assay and northern blot. Besides the stability of the luciferase and
mRNA, additional mechanisms may exist that contribute to the
upregulation of Id3 expression at transcription level following
anti-IgM stimulation. These results suggest that the mIg-mediated
upregulation of Id3 expression is controlled, at least in part,
through transcriptional regulation, as assessed by luciferase assay.
Discussion
Id proteins, a member of the HLH
family proteins, play a crucial role in proliferation,
differentiation, and apoptosis in a variety of cells including
lymphocytes[9-11]. The mature B cells from Id3-deficient
mice failed to proliferate in response to anti-IgM, whereas they
showed proliferation comparable to those from control mice in
response to LPS or CD40L[14], suggesting that Id3
promotes mIg-mediated B cell growth, as demonstrated in some cell
types[11]. However, WEHI-231 cells, representing immature
B cells, displayed growth arrest at the G1 phase of the cell cycle,
accompanied by upregula-tion of Id3 mRNA following stimulation with
anti-IgM[15]. In this study we examined whether the mIg-mediated
upregula-tion of Id3 mRNA expression resulted from transcriptional
activation and found that anti-IgM upregulated Id3 expression at
least through transcriptional activation.
The nucleotide sequences of the
5'-upstream fragments isolated from WEHI-231 genomic DNA were
confirmed to be identical with the published sequences[18]
(GenBank accession number, AL935264). Consistent with the
observation of Yeh and Lim[18] using C2C12 muscle cells,
the 254-bp fragment had substantial basal promoter activity of the
Id3 gene (Figure 3). Indeed, several putative binding sites (ATF,
Sp1, Egr1, Cre) for transcription factors were
found using TRANSFAC databases[18]. Interestingly, when
the longer fragments Id3/2k-Luc or Id3/1k-Luc was used, the basal
promoter activity decreased compared with Id3/254-Luc (Figure 3B).
These results might suggest that the promoter activity of the Id3
gene be regulated by both positive and negative regulatory elements,
as reported in the transcriptional regulation of a variety of genes
in eukaryotes[19]. A sufficient promoter activity was
also found in other several B lymphoid lineage cell lines BAL17 and
J558L (Li and Hata unpublished observation, 2003), although it is
not dependent on B cell development.
The promoter activity of the Id3
gene was increased following engagement of mIg, but not CD40
(Figures 4A and 4B), resulting in the upregulation of the Id3 mRNA
in WEHI-231 B lymphoma cells[15]. Although the Id3
upregulation through engagement of T cell receptor for antigen was
abrogated by MEK1 inhibitor PD98059[20], the mIg-mediated
upregulation of the Id3 message was not affected (Li and Hata,
unpublished observation), suggesting that antigen receptor-mediated
upregulation of Id3 expression is differently regulated between T
and B cells.
In contrast to anti-IgM, CD40L
decreased Id3 mRNA levels in WEHI-231 cells[15]. The
promoter activity of the Id3 gene in response to CD40L was somewhat
low, but not significant, compared with medium alone, suggesting
that CD40-mediated down-regulation of Id3 mRNA expression is
controlled post-transcriptionally. In our preliminary experiments,
pretreatment with proteasomal inhibitor lactacystin restored
CD40L-mediated down-regulation of Id3 protein expression (Li and
Hata, unpublished observation), as suggested by Bounpheng et al[21].
These findings suggest that CD40-mediated down-regulation is
controlled post-translationally.
Following an encounter with antigen,
immature B cells undergo growth arrest/apoptosis unless T
cell-derived signals such as CD40L are provided[7, 22].
Since transduction of Id3 gene into WEHI-231 cells results in growth
arrest at the G1 phase of the cell cycle[15], Id3 appears
to contribute to G1 arrest in immature B cells. The cell cycle
progression from G1 to S phase in mammalian cells is tightly
regulated by a cyclin-dependent kinase (CDK) and cyclin[23].
CDK activity is controlled by CDK inhibitors (CKIs) including p21Cip1
and p27Kip1[24]. Anti-IgM induced growth arrest through
an upregulation of p27Kip1 and down-regulation of cyclins[25].
It remains unclear how Id3 relates to p27Kip1-mediated
signalling pathway in B cells.
In contrast to our findings, Pan
et al reported that anti-IgM-induced proliferative responses
were severely reduced in mature B cells from Id3-deficient mice,
compared with those from control mice[14]. Id3 appears to
promote cell cycle progression in mature B cells upon encounter with
antigen, whereas it prevents cell cycle progression in immature B
cells, which could be accounted for by differential target(s) of Id3
molecule between mature and immature B cells. Experiments to examine
this possibility are in progress.
In the present study, we clarified
that engagement of mIg increased the promoter activity of the Id3
gene, probably resulting in an enhanced Id3 expression. The mIg-mediated
Id3 upregulation appears to contribute to growth arrest, which could
be reversed by the addition of CD40L, at least in part, through
down-regulation of Id3 expression. Our results would be valuable for
analysis of mIg-mediated unresponsiveness in B cells.
References
- 1 Nossal GJ. Immunologic
tolerance: collaboration between antigen and lymphokines.
Science 1989; 245: 147-53.
- 2 Klaus GG, Choi MS, Lam EW,
Johnson-Leger C, Cliff J. CD40: a pivotal receptor in the
determination of life/death decisions in B lymphocytes. Int Rev
Immunol 1997; 15: 5-31.
- 3 DeFranco AL. The complexity
of signaling pathways activated by the BCR. Curr Opin Immunol
1997; 9: 296-308.
- 4 Donjerkovic D, Scott DW.
Activation-induced cell death in B lymphocytes. Cell Res 2000;
10: 179-92.
- 5 Benhamou LE, Cazenave PA,
Sarthou P. Anti-immunoglobulins induce death by apoptosis in
WEHI-231 B lymphoma cells. Eur J Immunol 1990; 20: 1405-7.
- 6 Scott DW, Livnat D, Pennell
CA, Keng P. Lymphoma models for B cell activation and tolerance.
III. Cell cycle dependence for negative signalling of WEHI-231 B
lymphoma cells by anti-mu. J Exp Med 1986; 164: 156-64.
- 7 Scott DW, Chace JH, Warner
GL, O'Garra A, Klaus GG, Quill H. Role of T cell-derived
lymphokines in two models of B-cell tolerance. Immunol Rev 1987;
99: 153-71.
- 8 Tsubata T, Wu J, Honjo T.
B-cell apoptosis induced by antigen receptor crosslinking is
blocked by a T-cell signal through CD40. Nature 1993; 364:
645-8.
- 9 Massari ME, Murre C.
Helix-loop-helix proteins: regulators of transcription in
eucaryotic organisms. Mol Cell Biol 2000; 20: 429-40.
- 10 Engel I, Murre C. The
function of E- and Id proteins in lymphocyte development. Nat
Rev Immunol 2001; 1: 193-9.
- 11 Norton JD, Deed RW, Craggs
G, Sablitzky F. Id helix-loop-helix proteins in cell growth and
differentiation. Trends Cell Biol 1998; 8: 58-65.
- 12 Benezra R, Davis RL,
Lockshon D, Turner DL, Weintraub H. The protein Id: a negative
regulator of helix-loop-helix DNA binding proteins. Cell 1990;
61: 49-59.
- 13 Norton JD. ID
helix-loop-helix proteins in cell growth, differentiation and
tumorigenesis. J Cell Sci 2000; 113 (Pt 22): 3897-905.
- 14 Pan L, Sato S, Frederick JP,
Sun XH, Zhuang Y. Impaired immune responses and B-cell
proliferation in mice lacking the Id3 gene. Mol Cell Biol 1999;
19: 5969-80.
- 15 Hata K, Yoshimoto T,
Mizuguchi J. CD40 ligand rescues inhibitor of differentiation
3-mediated G1 arrest induced by anti-IgM in WEHI-231 B lymphoma
cells. J Immunol 2004; 173: 2453-61.
- 16 Zhao F, Vilardi A, Neely RJ,
Choi JK. Promotion of cell cycle progression by basic
helix-loop-helix E2A. Mol Cell Biol 2001; 21: 6346-57.
- 17 Hata K, Mizuguchi J. Genomic
organization and characterization of the promoter for the E2A
gene. Gene 2004; 325: 53-61.
- 18 Yeh K, Lim RW. Genomic
organization and promoter analysis of the murine Id3 gene. Gene
2000; 254: 163-71.
- 19 Ogbourne S, Antalis TM.
Transcriptional control and the role of silencers in
transcriptional regulation in eukaryotes. Biochem J 1998; 331
(Pt 1): 1-14.
- 20 Bain G, Cravatt CB, Loomans
C, Alberola-Ila J, Hedrick SM, Murre C. Regulation of the
helix-loop-helix proteins, E2A and Id3, by the Ras-ERK MAPK
cascade. Nat Immunol 2001; 2: 165-71.
- 21 Bounpheng MA, Dimas JJ,
Dodds SG, Christy BA. Degradation of Id proteins by the
ubiquitin-proteasome pathway. FASEB J 1999; 13: 2257-64.
- 22 DeFranco AL, Gold MR, Jakway
JP. B-lymphocyte signal transduction in response to
anti-immunoglobulin and bacterial lipopolysac-charide. Immunol
Rev 1987; 95: 161-76.
- 23 Morgan DO. Cyclin-dependent
kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev
Biol 1997; 13: 261-91.
- 24 Sherr CJ, Roberts JM. CDK
inhibitors: positive and negative regulators of G1-phase
progression. Genes Dev 1999; 13: 1501-12.
- 25 Ezhevsky SA, Toyoshima H,
Hunter T, Scott DW. Role of cyclin A and p27 in anti-IgM induced
G1 growth arrest of murine B-cell lymphomas. Mol Biol Cell 1996;
7: 553-64.
|